Browse diseases

…ze treatment selection for patients with early-stage inoperable NSCLC. If validated, it could serve as a foundation for a treatment-f…

…luminates the complexity of long-term outcomes in patients with NSCLC treated with pembrolizumab, uncovering dynamic, non-linear prog…

…) therapy remains a major challenge for cancer immunotherapy in non-small cell lung cancer (NSCLC). Gut microbial metabolites can influence immunotherapy …

… instance, A*02:01-specific LOH was linked to worse survival in CRC (HR 0.5355, 95% CI 0.2991 to 0.9589, p=0.0094) but showed a tre…

…andomised controlled trial of an intervention for patients with metastatic oncogene-driven NSCLC, Patient-centred, Optimal Integration of Survivorship and palli…

…c setting and 27.3% in second-line or later lines of treatment. Lung cancer (29.6%) and breast cancer (24.4%) were the most frequently stud…

…Background Small cell lung cancer (SCLC) is a recalcitrant malignancy with limited responses to i…

…Background and Importance Non-squamous non-small-cell lung cancer (NSCLC) remains one of the leading causes of cancer-related mor…

…kbone for advanced, driver-negative non-small cell lung cancer (NSCLC), delivering meaningful survival gains; yet for most, disease c…

…Objective Our study examines how non-small cell lung cancer (NSCLC) survivors undergoing immunotherapy can experience reduc…

…C.Results At the data cutoff of July 4, 2025, 119 patients with nonsquamous NSCLC and 125 with squamous NSCLC were enrolled in Parts 1 and 2, res…

…T03546829).Reference Enhancing outcomes in medically inoperable early-stage NSCLC with gut-targeted antibiotics and stereotactic body radiotherap…